Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
FDA approves Japan’s Otsuka Alzheimer’s anti-anxiety drug
- By Newsdesk
- Japan
- May 12, 2023
Otsuka Pharmaceutical's brexiprazole has been approved by the US Food and Drug Administration (FDA) for the treatment of anxiety in Alzheimer's disease patients. According to the manufacturer, its development is a forerunner in the field of drugs for the treatment of such conditions in Alzheimer's patients.
The drug was co-developed with the Danish pharmaceutical company Lundbeck and was previously approved in the United States for the treatment of adults with major depression and schizophrenia.
Patients who exhibit signs of aggression, anxiety, or intermittent restlessness should take brexiprazole. This is a result of the disease, which causes the brain to lose its ability to cope with external stimuli. Currently, such patients are sedated using non-pharmacological tools, or they are given antipsychotics and antidepressants, both of which can have serious side effects.